
Ozempic’s Surge in Egypt Sparks Medical Praise, Public Demand, and Growing Fears
Novo Nordisk’s once‐weekly injectable, Ozempic (semaglutide), originally developed for type 2 diabetes, has increasingly attracted attention in Egypt, not just for its blood-sugar-lowering benefits, but for its marked weight‐loss effect too. Clinical …